pharmacokinetics of tacrolimus early after transplantation
What is it about?
Early after heart and lung transplantation, it is difficult to dose tacrolimus correctly, which leads to (nephro-)toxicity. The significantly altered pharmacokinetics in this critical phase are due to fluctuating drug absorption, changed protein metabolism, anemia and (multi-)organ failure. This review focuses on the tacrolimus pharmacokinetics, discusses relevant factors influencing the unbound tacrolimus concentrations and tacrolimus toxicity early after heart and lung transplantation.
Why is it important?
Morbidity and mortality after heart and lung transplantation are influenced by renal injury. Tacrolimus is the first choice immunosuppressive drug for heart and lung transplant recipients in the early phase post transplantation. Treatment with tacrolimus often deteriorates renal function. Consequently, improving tacrolimus management in heart and lung transplant recipients is of utmost importance.
The following have contributed to this page: Professor Jan Meulenbelt, Ms Maaike A. Sikma, and Prof Marianne C Verhaar
In partnership with: